Head to head
Ironwood Pharmaceuticals vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: IRWD · TAK
IRWD
Ironwood Pharmaceuticals
3.75+3.31%
1-year price shape — +147% over the period
Quant Rating B · 83/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Ironwood Pharmaceuticals edges it on the scoreable measures. Ironwood Pharmaceuticals has the highest Quant Rating (83); Ironwood Pharmaceuticals has done best over the past year (+147%); Ironwood Pharmaceuticals earns the most per share.
| IRWD | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 3.75 | 18.37 |
| Change today | +3.31% | +1.49% |
| 1-year return | +146.7% | +29.2% |
| Market cap | $619.65M | $58.68B |
| 52-week range | 1.41 – 5.78 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | 4.75 | -55.67 |
| P/E percentile, own 5-yr range | 53rd | 4th |
| P/B | -3.83 | 1.23 |
| Dividend yield | 0.00% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | 0.15 | -0.31 |
| Net profit (TTM) | $24.79M | $-977.54M |
| Revenue (TTM) | $389.32M | $4.62T |
| Revenue growth (YoY) | +32.6% | +10.2% |
| Gross margin | 100.0% | 65.5% |
| Operating margin | 60.6% | 10.4% |
| Net margin | 33.4% | -3.5% |
| Free cash flow (TTM) | $185.55M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 99.0% | 51.5% |
| Insider activity (12mo) | 29 buy / 21 sell | 22 buy / 28 sell |
| Short interest (% of float) | 11.3% | 0.1% |
| Analyst consensus | 100% buy (1) | 100% buy (1) |
| Analyst price target | -- | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | B (83) | C (70) |
| Company | ||
| Employees | 100 | 47,029 |
| Founded | 1998 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.